# idiopathic pulmonary fibrosis (IPF) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 15446
- Completion tokens: 5162
- Reasoning tokens: 0
- Total tokens: 20608
- API requests reported: 1
- Elapsed seconds: 67.918
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
## 1. Overall biological interpretation

The uploaded prognostic analysis contains 100 unique genes (93 risk-associated, 7 protective-associated), all with FDR ≤ 0.01. The dominant signal is a large set of genes whose higher expression is associated with increased all-cause mortality risk in IPF lung tissue. The biological themes are broadly consistent with the known pathology of IPF: epithelial injury and aberrant repair, innate immune/neutrophilic inflammation, extracellular matrix remodeling, and growth factor signaling. However, the statistical result is dominated by an extreme dynamic range (HR values from ~10⁻²² to ~10²¹), which signals probable technical artifacts and warrants caution in interpreting individual effect sizes.

**Data-quality warning:** Several rows carry biologically implausible HR values (e.g., MIR221 HR=1.93e-22, HCN4 HR=1.93e+21, CONTROL_A_33_P3222196 HR=5.18e+21). These are almost certainly artifacts of near-zero variance or quasi-complete separation in the survival model for these probes/genes. The ledger flags XLOC_003303 as having direction conflict across duplicate rows. These extreme values should not be interpreted as meaningful prognostic effect sizes. The interpretable signal lies in the genes with HR values in the ~2–4 range (e.g., HTRA1, MARCKS, BASP1, CYP4F3, RAB3IL1, MERTK, KCNJ15), which form coherent biological programs.

## 2. Core biological programs

### Program 1: Innate immune/neutrophilic inflammation and NF-κB signaling
- **Direction:** Risk-associated (higher expression → worse survival)
- **Supporting genes:** S100A12, S100A14, CXCL1, CXCL14, CXCR1, CCL7, CD177, SELL, MMP25, SPP1, STAB1, CYP4F3
- **Pathway:** GO: Neutrophil Migration (GO:1990266); KEGG: Chemokine signaling pathway; Reactome: Neutrophil degranulation
- **Explanation:** Multiple chemokines (CXCL1, CXCL14, CCL7), a chemokine receptor (CXCR1), neutrophil markers (CD177, SELL, MMP25), and S100 alarmins (S100A12, S100A14) converge on neutrophil recruitment and activation. S100A12 is annotated for RAGE receptor binding and NF-κB activation via TAK1/TRAF6 (Reactome R-HSA-445989, R-HSA-933542). This is coherent with IPF, where neutrophilic inflammation is associated with worse outcomes.
- **Evidence strength:** Moderate. Multiple independent genes support the program; GO/KEGG/Reactome annotations align. Limitation: this is pathway/ontology evidence, not an enrichment statistic computed from the uploaded table; no independent-cohort statistic is available.

### Program 2: Epithelial injury, aberrant epithelial repair, and mucin/surfactant dysregulation
- **Direction:** Risk-associated
- **Supporting genes:** MUC1, MUC21, SFTPB, SFTA2, KRT17, KRT23, SPRR1A, CEACAM6, CEACAM7, AGR3, SLC34A2, PRSS8, MAL2, PKP3
- **Pathway:** GO: Antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844); KEGG: Epithelial cell signaling in Helicobacter pylori infection (as a general epithelial stress pathway)
- **Explanation:** Mucins (MUC1, MUC21), surfactant components (SFTPB, SFTA2), keratins (KRT17, KRT23), cornified envelope proteins (SPRR1A), and epithelial transporters (SLC34A2) collectively indicate aberrant alveolar epithelial cell state—a hallmark of IPF where injured alveolar type II cells undergo metaplastic changes.
- **Evidence strength:** Moderate. Multiple independent genes; tissue expression evidence (HPA/GTEx records). Limitation: some genes (e.g., SFTPB) may reflect normal alveolar epithelium content rather than disease-specific signaling; cell-composition effects are a major confounder.

### Program 3: Extracellular matrix remodeling and TGF-β/fibrotic signaling
- **Direction:** Risk-associated
- **Supporting genes:** HTRA1, EFEMP1, FBLIM1, CHST15, SPP1, F5, DYSF, BMP6, GALNT14, TPST1, HS3ST1
- **Pathway:** GO: Extracellular matrix organization; Reactome: Extracellular matrix organization (R-HSA-1474244, inferred from gene set)
- **Explanation:** HTRA1 (a serine protease involved in matrix degradation and TGF-β regulation), EFEMP1 (fibulin family ECM protein), CHST15 (chondroitin sulfotransferase), SPP1 (osteopontin, a well-known IPF biomarker), and BMP6 (TGF-β superfamily) converge on matrix turnover and fibrotic signaling. GALNT14 and TPST1 modify ECM/secreted proteins post-translationally.
- **Evidence strength:** Moderate. Multiple genes; SPP1 and HTRA1 have prior IPF literature. Limitation: pathway assignment is based on gene function rather than a formal enrichment test.

### Program 4: Growth factor receptor signaling (MET/HGF, NRG1/EGFR, Hedgehog)
- **Direction:** Risk-associated (MET, HGF, NRG1, SPRY2); protective (IHH, MIR221)
- **Supporting genes:** MET, HGF, NRG1, SPRY2, MARCKS, RGL1, IHH, MIR221
- **Pathway:** KEGG: EGFR tyrosine kinase inhibitor resistance (inferred); Reactome: Signaling by MET (R-HSA-6806834, inferred)
- **Explanation:** MET and its ligand HGF are both risk-associated; NRG1 signals through EGFR/ERBB receptors; SPRY2 is a negative feedback regulator of receptor tyrosine kinase signaling. The STRING network records show EGFR as a hub connecting EFEMP1, HGF, MET, MUC1, NRG1 (pathway co-membership/STRING edges, not direct physical interaction). MIR221 and IHH appear as protective, but their HR values (1.93e-22) are in the artifact range and should not be interpreted.
- **Evidence strength:** Weak-to-moderate. The EGFR/MET connection is supported by STRING records but these are predicted/pathway-level associations, not direct physical interaction evidence. The protective direction of IHH/MIR221 is statistically unreliable.

### Program 5: Metabolic reprogramming and oxidative stress response
- **Direction:** Risk-associated
- **Supporting genes:** SLC7A11, SLC39A8, STEAP4, ACOX2, ALDH1A3, SLC6A8, CYP4F3, SOD3
- **Pathway:** KEGG: Ferroptosis (SLC7A11 is a canonical ferroptosis regulator); GO: cellular response to oxidative stress
- **Explanation:** SLC7A11 (cystine/glutamate antiporter, ferroptosis suppressor), STEAP4 (oxidoreductase), ACOX2 (peroxisomal β-oxidation), ALDH1A3 (aldehyde dehydrogenase), and CYP4F3 (fatty acid ω-hydroxylase) collectively indicate altered redox balance and lipid metabolism. SOD3 (extracellular superoxide dismutase) is also risk-associated, which is counterintuitive given its antioxidant role—this suggests the signal may reflect cell-type composition rather than a simple antioxidant/pro-oxidant axis.
- **Evidence strength:** Moderate for gene-level associations; weak for a unified "program" because the genes span several distinct metabolic processes. Limitation: risk-associated SOD3 conflicts with its canonical protective antioxidant function, suggesting possible confounding.

## 3. Key genes and interaction modules

### 1. S100A12 / S100A14 module (innate immune alarmins)
- **Statistics:** S100A12 HR=2.53 (FDR=5.49e-06); S100A14 HR=2.57 (FDR=8.06e-06), both risk-associated.
- **Role:** S100A12 binds RAGE (AGER) and activates NF-κB via TAK1/TRAF6 (Reactome); S100A14 has similar S100 family functions.
- **Interaction type:** STRING records show S100A12 interacting with AGER (confidence 0.999), TLR4 (0.970), and S100A8/A9 (0.940–0.995). These are predicted/curated interactions from STRING, not necessarily direct physical binding verified in IPF lung. The S100A12–AGER–TLR4 relationship is best described as **regulatory/pathway co-membership** with strong STRING confidence, pending experimental confirmation.

### 2. HTRA1
- **Statistics:** HR=4.30 (FDR=2.57e-06), the largest interpretable HR in the dataset.
- **Role:** Serine protease regulating TGF-β bioavailability and matrix degradation; central to fibrotic remodeling.
- **Interaction type:** No direct interaction evidence in the retrieved records; role is inferred from its protease function and literature. **Pathway co-membership** with ECM organization.

### 3. MERTK
- **Statistics:** HR=3.70 (FDR=1.05e-05), risk-associated.
- **Role:** Tyrosine kinase receptor mediating efferocytosis (clearance of apoptotic cells); in IPF, defective or aberrant efferocytosis contributes to fibrotic progression.
- **Interaction type:** No direct interaction evidence retrieved; role is inferred from receptor biology. **Indirect/putative** relationship to fibrosis.

### 4. CXCR1 / CXCL1 / CXCL14 module (neutrophil chemotaxis)
- **Statistics:** CXCR1 HR=3.28; CXCL1 HR=2.99; CXCL14 HR=2.38, all risk-associated.
- **Role:** CXCR1 is the receptor for CXCL1 (and CXCL8); CXCL14 is a chemokine with antimicrobial activity. STRING records show CXCL5/CXCL6 as connectors (CXCL1, CXCL14, CXCR1, CCL7).
- **Interaction type:** CXCL1–CXCR1 is a **receptor–ligand (direct physical) interaction** by definition of chemokine biology; CXCL14–CXCR1 is **putative** since CXCL14's receptor is not definitively CXCR1. The STRING edges are pathway co-membership unless direct binding is documented.

### 5. MET / HGF / SPRY2 module (RTK signaling)
- **Statistics:** MET HR=2.53; HGF HR=2.93; SPRY2 HR=3.26, all risk-associated.
- **Role:** MET is the receptor for HGF; SPRY2 is a feedback inhibitor of RTK signaling. Both ligand and receptor being risk-associated is notable.
- **Interaction type:** HGF–MET is a **direct physical (receptor–ligand) interaction**. SPRY2–MET is a **regulatory interaction** (SPRY2 inhibits MET signaling). STRING records also link CBL (E3 ligase) to MET and SPRY2, indicating a regulatory module.

### 6. SPP1 (osteopontin)
- **Statistics:** HR=3.40 (FDR=3.99e-05), risk-associated.
- **Role:** Secreted matricellular protein; established IPF biomarker associated with disease progression and macrophage activation.
- **Interaction type:** STRING records link SPP1 with CD44 (SELL, SLC7A11, SPP1) and FN1 (CEACAM6, HGF, SPP1)—**pathway co-membership/ligand–receptor** (SPP1–CD44 is a documented receptor–ligand pair).

### 7. MARCKS / BASP1 module (membrane-associated signaling)
- **Statistics:** MARCKS HR=4.00; BASP1 HR=3.77, both risk-associated.
- **Role:** MARCKS is a PKC substrate regulating actin dynamics and mucin secretion; BASP1 is a related membrane-associated protein.
- **Interaction type:** STRING records show both connecting to CALML4/CALML6 (calmodulin-like proteins)—**co-expression/pathway co-membership**; no direct physical interaction evidence retrieved.

### 8. SLCO4A1 / SLC7A11 / SLC39A8 (transporter/metabolic module)
- **Statistics:** SLCO4A1 HR=2.97; SLC7A11 HR=3.52; SLC39A8 HR=3.22, all risk-associated.
- **Role:** Organic anion, cystine/glutamate, and zinc transporters respectively; collectively indicate altered epithelial/immune cell metabolism.
- **Interaction type:** No direct interaction evidence; **pathway co-membership** in metabolic/transport processes.

### 9. CEACAM6 / CEACAM7 / MUC1 module (epithelial surface glycoproteins)
- **Statistics:** CEACAM6 HR=2.66; CEACAM7 HR=2.31; MUC1 HR=2.32, all risk-associated.
- **Role:** Cell-surface glycoproteins marking aberrant epithelial differentiation; MUC1 is a known IPF biomarker.
- **Interaction type:** Co-expression/pathway co-membership; no direct physical interaction evidence retrieved.

### 10. KCNJ15 / MRVI1 / MRVI1-AS1 module
- **Statistics:** KCNJ15 HR=3.58; MRVI1 HR=3.85; MRVI1-AS1 HR=3.23, all risk-associated.
- **Role:** KCNJ15 is a potassium channel; MRVI1 is a calcium-sensitizing protein; the antisense RNA MRVI1-AS1 may regulate MRVI1.
- **Interaction type:** MRVI1-AS1–MRVI1 is a **putative regulatory interaction** (antisense RNA regulation); KCNJ15–MRVI1 relationship is **indirect/putative**.

## 4. Validation priorities

### Priority 1: Cell-composition deconvolution (Confounding/composition check)
- **Why:** Many risk-associated genes (S100A12, CD177, MMP25, CXCR1, SELL) are neutrophil/macrophage markers; others (SFTPB, SFTA2, SLC34A2) mark alveolar epithelium. The survival signal may reflect the proportion of inflammatory versus epithelial cells in the biopsy rather than cell-intrinsic prognostic biology.
- **Dataset evidence:** The co-occurrence of neutrophil, macrophage, and epithelial markers in the same risk direction is a red flag for composition effects.
- **External evidence:** IPF lung tissue shows variable inflammatory infiltrate; single-cell studies show distinct epithelial, macrophage, and fibroblast states.
- **Next step:** Perform cell-type deconvolution (e.g., CIBERSORTx, BisqueRNA) using a lung-specific reference; correlate estimated cell fractions with survival; test whether the gene–survival associations persist after adjusting for cell fractions.
- **Status:** **Supported hypothesis** (the confounding is plausible but not demonstrated in this dataset).

### Priority 2: S100A12/RAGE/NF-κB axis as a mechanistic and therapeutic target
- **Classification:** Mechanistic hypothesis + Therapeutic target
- **Why:** S100A12 has a strong HR (2.53) and clear pathway annotation (RAGE binding, NF-κB activation); it connects to the broader neutrophilic inflammation program.
- **Dataset evidence:** Direct HR/FDR support; Reactome/STRING records for NF-κB activation and AGER/TLR4 interaction.
- **External evidence:** S100 proteins are implicated in IPF and other fibrotic diseases; RAGE signaling is a recognized fibrosis pathway. However, no drug-target evidence specific to IPF was retrieved from ChEMBL/ClinicalTrials for S100A12.
- **Next step:** Measure S100A12 protein in IPF plasma/BAL and test whether it predicts mortality independent of clinical variables; test RAGE blockade in IPF-relevant models.
- **Status:** **Supported hypothesis** (pathway evidence is strong; causal role in IPF mortality is not established).

### Priority 3: MET/HGF signaling module validation
- **Classification:** Mechanistic hypothesis
- **Why:** Both MET and HGF are risk-associated, which is paradoxical given HGF is often considered protective/regenerative in lung injury. This paradox needs resolution.
- **Dataset evidence:** MET HR=2.53; HGF HR=2.93; SPRY2 HR=3.26.
- **External evidence:** HGF is classically described as pro-repair in IPF; however, in some contexts HGF/MET signaling promotes fibroblast activation. The retrieved STRING records show EGFR as a hub with HGF/MET/NRG1.
- **Next step:** Cell-type-resolved analysis (single-cell or spatial transcriptomics) to determine whether MET/HGF signal in epithelial cells, fibroblasts, or macrophages; functional assays with MET inhibitors in IPF models.
- **Status:** **Exploratory hypothesis** (direction conflicts with some literature expectations).

### Priority 4: SPP1 as a prognostic biomarker
- **Classification:** Biomarker
- **Why:** SPP1 (osteopontin) is a well-established IPF biomarker; its risk-associated HR (3.40) here is consistent with prior literature.
- **Dataset evidence:** Direct HR/FDR support.
- **External evidence:** Multiple prior IPF studies link SPP1 expression to disease severity and mortality; SPP1 is a macrophage marker in IPF single-cell studies.
- **Next step:** Validate in an independent IPF cohort with plasma SPP1 and survival data; assess whether SPP1 adds prognostic value beyond GAP index.
- **Status:** **Supported hypothesis** (dataset + literature concordant; independent-cohort statistic not supplied here).

### Priority 5: HTRA1 functional validation in fibrosis
- **Classification:** Mechanistic hypothesis
- **Why:** HTRA1 has the highest interpretable HR (4.30) and a clear mechanistic role in TGF-β regulation and ECM turnover.
- **Dataset evidence:** Direct HR/FDR support.
- **External evidence:** HTRA1 is implicated in age-related diseases and matrix remodeling; its role in IPF is less established than SPP1, making it a novel candidate.
- **Next step:** Genetic or pharmacologic perturbation of HTRA1 in IPF fibroblast or bleomycin models; assess TGF-β activation and matrix deposition.
- **Status:** **Exploratory hypothesis** (novel candidate with plausible mechanism).

## 5. Evidence grounding

| Conclusion | Direct dataset evidence | Pathway/ontology | Interaction/regulatory | Disease association | Expression/tissue | Literature |
|---|---|---|---|---|---|---|
| Neutrophilic inflammation is a risk program | Yes (S100A12, CXCL1, CD177, etc., HR>2, FDR<0.01) | Yes (GO:Neutrophil Migration, Chemokine signaling) | Yes (S100A12–AGER–TLR4, STRING) | Yes (IPF known to involve neutrophils) | Yes (HPA/GTEx) | Partial (IPF neutrophil literature) |
| Epithelial dysregulation is a risk program | Yes (MUC1, SFTPB, KRT17, etc.) | Yes (antimicrobial peptide GO) | Not retrieved | Yes (IPF epithelial injury is core) | Yes | Partial |
| ECM remodeling is a risk program | Yes (HTRA1, EFEMP1, SPP1) | Yes (ECM organization) | Partial (SPP1–FN1–CD44) | Yes | Yes | Yes (SPP1 in IPF) |
| MET/HGF signaling is risk-associated | Yes (MET, HGF, SPRY2) | Partial | Yes (HGF–MET ligand–receptor; STRING EGFR hub) | Mixed (HGF usually protective) | Yes | Mixed/conflicting |
| S100A12–RAGE–NF-κB axis | Yes (S100A12 HR=2.53) | Yes (Reactome NF-κB) | Yes (STRING AGER/TLR4) | Yes (RAGE in fibrosis) | Yes | Partial |
| IHH/MIR221 protective | Unreliable (artifact-range HR) | Not assessed | Not assessed | Not assessed | Not assessed | Insufficient |

**Independence note:** The pathway/ontology, STRING, and literature records may share underlying publications or prediction models and are not automatically independent. The uploaded HR/FDR values are the only direct statistical evidence. External statistical validation was not performed—no independent-cohort statistic was supplied.

## 6. Limitations and alternative explanations

### 1. Cell-composition confounding (most important)
The co-occurrence of neutrophil (S100A12, CD177, MMP25, CXCR1), macrophage (SPP1, STAB1, MERTK), and epithelial (SFTPB, SFTA2, MUC1) markers in the risk direction strongly suggests that the survival signal may partly reflect the inflammatory and epithelial cellular content of the biopsy. **Investigation:** deconvolution or single-cell validation; adjust survival models for estimated cell fractions.

### 2. Extreme HR values and model instability
HR values of 10⁻²² to 10²¹ indicate quasi-complete separation or near-zero variance for those features (MIR221, IHH, HCN4, OR2M2, CONTROL probes, DKFZP434L187, XLOC_003303). These are statistically degenerate and should be excluded from biological interpretation. **Investigation:** re-fit with Firth's penalized likelihood or drop near-constant features; check for duplicate probe issues (29 duplicated genes/probes in the ledger).

### 3. Disease severity and treatment exposure
IPF patients at different disease stages and on different treatments (antifibrotics, corticosteroids, oxygen) will have different transcriptomes. The uploaded table does not include adjustment for disease severity (FVC, DLCO) or treatment. **Investigation:** confirm whether the survival model was adjusted for clinical covariates; if not, re-analyze with adjustment.

### 4. Batch/platform effects and probe annotation issues
The presence of CONTROL_A probes, XLOC (Cufflinks) identifiers, lincRNA coordinates, and DKFZP clones indicates a mixed annotation platform. 29 duplicated genes/probes and one direction-conflict flag (XLOC_003303) suggest annotation or mapping issues. **Investigation:** remap to a consistent reference (e.g., GENCODE) and collapse to gene-level with a defined rule (e.g., max HR or meta-analysis).

### 5. Association-versus-causation ambiguity
All findings are associations with mortality in a cross-sectional transcriptome. Higher expression of a gene may reflect the disease process, the host response, or the cellular composition—not a causal driver of mortality. **Investigation:** functional perturbation studies; Mendelian randomization using eQTL data; longitudinal sampling.

## Summary

The uploaded data support a coherent interpretation centered on **neutrophilic inflammation, aberrant epithelial differentiation, ECM remodeling, and growth factor signaling** as risk-associated programs in IPF mortality. The most defensible high-priority candidates for follow-up are **S100A12** (mechanistic, NF-κB/RAGE axis), **SPP1** (biomarker with prior literature support), and **HTRA1** (novel, high-HR candidate). The strongest caveat is that the risk signal may be substantially confounded by cell composition, and the extreme HR values for several genes indicate technical artifacts that must be excluded before further interpretation. External statistical validation was not performed; all conclusions beyond the direct HR/FDR associations should be considered supported or exploratory hypotheses rather than established evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=28, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
